Compare COEP & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COEP | PETS |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 61.6M |
| IPO Year | N/A | 2003 |
| Metric | COEP | PETS |
|---|---|---|
| Price | $11.72 | $2.37 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 32.8K | ★ 105.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $273,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $1.57 |
| 52 Week High | $21.41 | $4.32 |
| Indicator | COEP | PETS |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 25.37 |
| Support Level | $10.98 | N/A |
| Resistance Level | $13.23 | $2.93 |
| Average True Range (ATR) | 0.94 | 0.11 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 41.06 | 14.04 |
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.